Industry News
Biotechnology Industry News
BeOne Medicines has shaken up its…
BeOne Medicines has shaken up its early pipeline, dropping five phase 1 cancer programs and stopping a phase 2 arthritis trial based on new data.
Ascendis Pharma has ended internal…
Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an asset it once tipped for accelerated approval.
For people living with exocrine…
For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is a regimen that can include up to 40 pills a day. With a $250 million investment from Blackstone Life
Entrada Therapeutics’ Duchenne…
Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the biotech’s stock as investors evaluated the fallout from a key readout expected to validate its platform.
The recent run of first-quarter…
The recent run of first-quarter earnings results marked a shift for Big Pharmas away from AI hype and toward explaining how the technology is being applied in practice.
Ipsen has set aside the two drug…
Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely.
The company announced it has…
The company announced it has concluded development of the plasma kallikrein inhibitor, which was being studied to treat diabetic macular edema.
GSK has found another potential…
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides.
The buyout, which includes up to…
The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse linked to improved outcomes in a pair of phase 2 trials last year.
The placebo-adjusted result fell…
The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, but the biotech’s stock jumped in premarket trading.
Novo Nordisk’s CEO has insisted…
Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending work on a single-chamber delivery device.
With Gilead’s $7.8 billion buyout…
With Gilead's $7.8 billion buyout of Arcellx complete, the California pharma is consolidating some of the workforce at the acquired company.
Chris Gibson built the pioneering…
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his replacement,
In the last three years,…
In the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future of his company. He used to be “obsessed with pharma deals,” he
Madrigal Pharmaceuticals has…
Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steatohepatitis (MASH).
Pfizer’s $2.3 billion bet on…
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the second and final clinical-stage candidate from that acquisition.
A second phase 3 trial of Viridian…
A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blockbuster market.
After pausing a trial for a…
After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals has now decided to discontinue the program entirely.
After some tough feedback from the…
After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic review and set out a plan to whittle down its headcount by 75%.
Mirum Pharmaceuticals is moving…
Mirum Pharmaceuticals is moving toward an FDA filing after its small molecule volixibat significantly reduced severe itching in patients with a rare liver disease.